SAB Biotherapeutics, Inc. (SABS) earnings
SABS earnings moved a median of -3.00% by the close. Quarterly and annual SABS reports and results, each read against the price at its own news timestamp. Back to the SABS overview →
17 measured SABS earnings events.
Where these SABS earnings landedvs 17 measured SABS earnings reactions
| Middle 50% of SABS earnings reactions | -6.21% to +1.83% |
|---|---|
| Median reaction (to close) | -3.00% |
| Measured reactions | 17 |
Point-in-time · zero look-ahead
Half of the 17 SABS earnings events with a measured close landed between -6.21% and +1.83%; 41% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q SAB Biotherapeutics, For: Jun 30 | SEC filing · Form 10-Q | -0.27% | +2.39% | |
| SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET | Press release | +2.29% | +2.01% | |
| Form 10-Q SAB Biotherapeutics, For: Mar 31 | SEC filing · Form 10-Q | -2.63% | -4.74% | |
| SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET | Press release | -0.55% | +0.55% | |
| Form 10-K SAB Biotherapeutics, For: Dec 31 | SEC filing · Form 10-K | +0.25% | +1.24% | |
| Form 10-Q SAB Biotherapeutics, For: Sep 30 | SEC filing · Form 10-Q | +2.31% | +6.93% | |
| Form 10-Q SAB Biotherapeutics, For: Jun 30 | SEC filing · Form 10-Q | +2.28% | +1.83% | |
| Form 10-Q SAB Biotherapeutics, For: Mar 31 | SEC filing · Form 10-Q | — | +4.07% | |
| Form 10-K SAB Biotherapeutics, For: Dec 31 | SEC filing · Form 10-K | — | -6.21% | |
| Form 10-Q SAB Biotherapeutics, For: Sep 30 | SEC filing · Form 10-Q | +2.53% | -17.21% | |
| SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update | Press release | +2.53% | -17.21% | |
| Form 10-Q SAB Biotherapeutics, For: Jun 30 | SEC filing · Form 10-Q | — | -12.26% | |
| SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates | Press release | — | -12.26% | |
| Form 10-Q SAB Biotherapeutics, For: Mar 31 | SEC filing · Form 10-Q | +6.00% | -3.00% | |
| Form NT 10-Q SAB Biotherapeutics, For: Mar 31 | SEC filing · Form NT | -1.74% | -3.97% | |
| Form 10-K SAB Biotherapeutics, For: Dec 31 | SEC filing · Form 10-K | +0.00% | -4.88% | |
| Form 10-Q SAB Biotherapeutics, For: Sep 30 | SEC filing · Form 10-Q | — | +0.00% |
Keep exploring
More SABS: analyst actions → · SEC filings → · SABS overview →